Browsing Tag
NUZ-001
5 posts
Neurizon Therapeutics (ASX: NUZ) NUZ-001 activates dual protein clearance pathways in ALS neuronal study
Neurizon Therapeutics NUZ-001 activates two protein clearance pathways in ALS neurons. Read what the preclinical data means ahead of the HEALEY trial.
Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.
Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.
Why investors are watching Neurizon Therapeutics (ASX: NUZ) ahead of FDA clearance for NUZ-001
Neurizon Therapeutics (ASX: NUZ) secures A$5m to fund ALS trial entry. Can NUZ-001 succeed in the HEALEY ALS Platform Trial and change the biotech landscape?
FDA delay shifts Neurizon Therapeutics (ASX: NUZ) ALS trial start — Can Q4 still deliver a win?
FDA delays decision on Neurizon’s NUZ-001 ALS trial to October, but manufacturing, regulatory, and trial readiness milestones keep Q4 start within reach.
Neurizon Therapeutics secures global licence from Elanco to fast-track NUZ-001 commercialisation
Find out how Neurizon’s global licence with Elanco is accelerating ALS therapy NUZ-001 and de-risking its path to market entry and clinical trials.